SUBSCRIBE
SUBSCRIBE

Phase 2

Drug Development
E-Data Can Transform Clinical Trials
August 9, 2007
 · 
1 min read
Drug Development
Pima Community College Offers New Clinical Trials Programs
August 8, 2007
 · 
1 min read
Drug Development
Court Rules Out Terminally Ill for Tests
August 8, 2007
 · 
1 min read
Drug Development
Drug Company Abbott GmbH Picks Singapore for Trial of New Cancer Drug
August 7, 2007
 · 
1 min read
Drug Development
Firms Should Still Carefully Consider Audit Trails for Clinical Trial Systems
August 6, 2007
 · 
1 min read
Drug Development
First Black-Owned Clinical Trial Firm Launches in South Africa
August 6, 2007
 · 
1 min read
Drug Development
Congress Urged to Act on Clinical Trial Registries and Databases
August 3, 2007
 · 
1 min read
Drug Development
University of Warwick Awarded £1 Million by Wolfson for new Clinical Trials Unit
August 3, 2007
 · 
1 min read
Drug Development
Clinical Setbacks for Toll-like Receptor 9 Agonists in Cancer
August 2, 2007
 · 
1 min read
Drug Development
Quality of Prospective Controlled Randomized Trials
August 2, 2007
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process
May 8, 2026
 · 
5 min read
Press Releases
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
 · 
13 min read
Press Releases
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren’s Syndrome in China
May 8, 2026
 · 
3 min read
Press Releases
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
May 8, 2026
 · 
12 min read
Press Releases
Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting
May 8, 2026
 · 
6 min read
Press Releases
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
May 8, 2026
 · 
8 min read
Press Releases
Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment
May 7, 2026
 · 
3 min read
Press Releases
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 7, 2026
 · 
12 min read
Press Releases
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
May 7, 2026
 · 
8 min read
Press Releases
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
May 7, 2026
 · 
6 min read
Press Releases
Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
May 7, 2026
 · 
7 min read
Press Releases
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 7, 2026
 · 
5 min read
Press Releases
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 7, 2026
 · 
15 min read
Press Releases
PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients
May 7, 2026
 · 
5 min read
Press Releases
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
 · 
18 min read
Press Releases
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
May 7, 2026
 · 
7 min read
Press Releases
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 7, 2026
 · 
1 min read
Press Releases
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
May 6, 2026
 · 
5 min read
Press Releases
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026
 · 
10 min read
Press Releases
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
 · 
14 min read
Load More